Carindacillin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Carindacillin
Accession Number
DB09319
Type
Small Molecule
Groups
Approved, Investigational
Description

Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of carbenicillin marketed by Pfizer as Geocillin. It is no longer marketed in the United States.

Structure
Thumb
Synonyms
  • 6β-{2-[(2,3-dihydro-1H-inden-5-yloxy)carbonyl]-2-phenylacetamido}-2,2-dimethylpenam-3α-carboxylic acid
  • Carbenicillin indanyl
  • Carindacilina
  • Carindacillin
  • Carindacilline
  • Carindacillinum
  • Indanyl carbenicillin
Product Ingredients
IngredientUNIICASInChI Key
Carbenicillin indanyl sodium4OUL81K2RT26605-69-6QFWPXOXWAUAYAB-XZVIDJSISA-M
Active Moieties
NameKindUNIICASInChI Key
CarbenicillinprodrugG42ZU72N5G4697-36-3FPPNZSSZRUTDAP-UWFZAAFLSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GeocillinTablet, film coated382 mg/1OralRoerig1972-10-262007-09-30Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
5V278481KE
CAS number
35531-88-5
Weight
Average: 494.56
Monoisotopic: 494.151157739
Chemical Formula
C26H26N2O6S
InChI Key
JIRBAUWICKGBFE-MNRDOXJOSA-N
InChI
InChI=1S/C26H26N2O6S/c1-26(2)20(24(31)32)28-22(30)19(23(28)35-26)27-21(29)18(15-7-4-3-5-8-15)25(33)34-17-12-11-14-9-6-10-16(14)13-17/h3-5,7-8,11-13,18-20,23H,6,9-10H2,1-2H3,(H,27,29)(H,31,32)/t18?,19-,20+,23-/m1/s1
IUPAC Name
(2S,5R,6R)-6-[3-(2,3-dihydro-1H-inden-5-yloxy)-3-oxo-2-phenylpropanamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
SMILES
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(=O)OC1=CC2=C(CCC2)C=C1)C1=CC=CC=C1)C(O)=O

Pharmacology

Indication

For the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria (due to susceptible strains Escherichia coli, Proteus mirabilis, Morganella morganii, Providencia rettgeri, Proteus vulgaris, Pseudomonas, Enterobacter, and Enterococci.). Also indicated in the treatment of prostatitis (due to susceptible strains Escherichia coli Enterococcus (S. faecalis), Proteus mirabilis Enterobacter sp.).

Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
APenicillin-binding protein
inhibitor
Gram positive and gram negative bacteria
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinCarindacillin may increase the anticoagulant activities of (R)-warfarin.
(S)-WarfarinCarindacillin may increase the anticoagulant activities of (S)-Warfarin.
4-hydroxycoumarinCarindacillin may increase the anticoagulant activities of 4-hydroxycoumarin.
AcemetacinAcemetacin may decrease the excretion rate of Carindacillin which could result in a higher serum level.
AcenocoumarolCarindacillin may increase the anticoagulant activities of Acenocoumarol.
Adenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Carindacillin.
AlcuroniumThe therapeutic efficacy of Alcuronium can be increased when used in combination with Carindacillin.
AmikacinThe serum concentration of Amikacin can be decreased when it is combined with Carindacillin.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Carindacillin.
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Carindacillin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. English AR, Retsema JA, Ray VA, Lynch JE: Carbenicillin indanyl sodium, an orally active derivative of carbenicillin. Antimicrob Agents Chemother. 1972 Mar;1(3):185-91. [PubMed:4558137]
External Links
ChemSpider
84127
ChEBI
52015
ChEMBL
CHEMBL1596
Wikipedia
Carindacillin
ATC Codes
J01CR50 — Combinations of penicillinsJ01CA05 — Carindacillin
FDA label
Download (63.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral382 mg/1
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00491 mg/mLALOGPS
logP3.57ALOGPS
logP3.63ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)3.29ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area113.01 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity128.25 m3·mol-1ChemAxon
Polarizability50.52 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
N-acyl-alpha amino acids and derivatives
Alternative Parents
Indanes / Penams / Benzene and substituted derivatives / Dicarboxylic acids and derivatives / Thiazolidines / Tertiary carboxylic acid amides / Azetidines / Carboxylic acid esters / Thiohemiaminal derivatives / Propargyl-type 1,3-dipolar organic compounds
show 9 more
Substituents
N-acyl-alpha amino acid or derivatives / Indane / Penam / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Beta-lactam / Tertiary carboxylic acid amide / Thiazolidine / Azetidine
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
penicillin (CHEBI:52015)

Targets

Kind
Protein group
Organism
Gram positive and gram negative bacteria
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Removes C-terminal D-alanyl residues from sugar-peptide cell wall precursors.

Components:
References
  1. Sainsbury S, Bird L, Rao V, Shepherd SM, Stuart DI, Hunter WN, Owens RJ, Ren J: Crystal structures of penicillin-binding protein 3 from Pseudomonas aeruginosa: comparison of native and antibiotic-bound forms. J Mol Biol. 2011 Jan 7;405(1):173-84. doi: 10.1016/j.jmb.2010.10.024. Epub 2010 Oct 23. [PubMed:20974151]
  2. Gotoh N, Nunomura K, Nishino T: Resistance of Pseudomonas aeruginosa to cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. J Antimicrob Chemother. 1990 Apr;25(4):513-23. [PubMed:2112536]
  3. Rodriguez-Tebar A, Rojo F, Damaso D, Vazquez D: Carbenicillin resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Aug;22(2):255-61. [PubMed:6821456]

Drug created on November 17, 2015 10:22 / Updated on July 13, 2019 00:53